Osteonecrosi avascolare del massiccio facciale in corso di terapia con bisfosfonati

Translated title of the contribution: Avascular jaw osteonecrosis associated with bisphophonate therapy

Chiara Broglia, Giuseppe Merlati, Francesco Valentino, Chiara Benatti, Paolo Gobbi, Edoardo Ascari

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The case of an IgAk myeloma showed the following common features with more than a hundred of patients described by the literature: osteonecrosis of the jaws, prolonged administration of bisphosphonates due to neoplastic skeletal lesions, antitumoral therapies and recent dental surgery. The antiangiogenetic effects of bisphosphonates can have an important pathogenetic role and a general dental treatment should be completed before the start of bisphosphonate administration.

Original languageItalian
Pages (from-to)140-144
Number of pages5
JournalRecenti Progressi in Medicina
Volume97
Issue number3
Publication statusPublished - Mar 2006

Fingerprint

Osteonecrosis
Diphosphonates
Jaw
Tooth
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Osteonecrosi avascolare del massiccio facciale in corso di terapia con bisfosfonati. / Broglia, Chiara; Merlati, Giuseppe; Valentino, Francesco; Benatti, Chiara; Gobbi, Paolo; Ascari, Edoardo.

In: Recenti Progressi in Medicina, Vol. 97, No. 3, 03.2006, p. 140-144.

Research output: Contribution to journalArticle

@article{62f12ff867144ea5a82a64e5049406af,
title = "Osteonecrosi avascolare del massiccio facciale in corso di terapia con bisfosfonati",
abstract = "The case of an IgAk myeloma showed the following common features with more than a hundred of patients described by the literature: osteonecrosis of the jaws, prolonged administration of bisphosphonates due to neoplastic skeletal lesions, antitumoral therapies and recent dental surgery. The antiangiogenetic effects of bisphosphonates can have an important pathogenetic role and a general dental treatment should be completed before the start of bisphosphonate administration.",
keywords = "Avascular osteonecrosis, Bisphosphonates, Multiple myeloma",
author = "Chiara Broglia and Giuseppe Merlati and Francesco Valentino and Chiara Benatti and Paolo Gobbi and Edoardo Ascari",
year = "2006",
month = "3",
language = "Italian",
volume = "97",
pages = "140--144",
journal = "Recenti Progressi in Medicina",
issn = "0034-1193",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
number = "3",

}

TY - JOUR

T1 - Osteonecrosi avascolare del massiccio facciale in corso di terapia con bisfosfonati

AU - Broglia, Chiara

AU - Merlati, Giuseppe

AU - Valentino, Francesco

AU - Benatti, Chiara

AU - Gobbi, Paolo

AU - Ascari, Edoardo

PY - 2006/3

Y1 - 2006/3

N2 - The case of an IgAk myeloma showed the following common features with more than a hundred of patients described by the literature: osteonecrosis of the jaws, prolonged administration of bisphosphonates due to neoplastic skeletal lesions, antitumoral therapies and recent dental surgery. The antiangiogenetic effects of bisphosphonates can have an important pathogenetic role and a general dental treatment should be completed before the start of bisphosphonate administration.

AB - The case of an IgAk myeloma showed the following common features with more than a hundred of patients described by the literature: osteonecrosis of the jaws, prolonged administration of bisphosphonates due to neoplastic skeletal lesions, antitumoral therapies and recent dental surgery. The antiangiogenetic effects of bisphosphonates can have an important pathogenetic role and a general dental treatment should be completed before the start of bisphosphonate administration.

KW - Avascular osteonecrosis

KW - Bisphosphonates

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=33646000835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646000835&partnerID=8YFLogxK

M3 - Articolo

C2 - 16700419

AN - SCOPUS:33646000835

VL - 97

SP - 140

EP - 144

JO - Recenti Progressi in Medicina

JF - Recenti Progressi in Medicina

SN - 0034-1193

IS - 3

ER -